IOVA SECURITIES NOTICE: Iovance Biotherapeutics Investors may have been Affected by Fraud - Contact BFA Law by July 14 if You Suffered LossesNEW YORK CITY, NY / ACCESS Newswire / June 26, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (
NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVANEW YORK CITY, NY / ACCESS Newswire / June 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (
NASDAQ:IOVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Levi & Korsinsky Reminds Iovance Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 14, 2025 - IOVANEW YORK - June 26, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (
NASDAQ: IOVA) of a class action securities lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVANEW YORK CITY, NY / ACCESS Newswire / June 25, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (
NASDAQ:IOVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Levi & Korsinsky Reminds Iovance Biotherapeutics, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 14, 2025 - IOVANEW YORK - June 25, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (
NASDAQ: IOVA) of a class action securities lawsuit.
BFA Law Notifies Iovance Biotherapeutics, Inc. (IOVA) Investors that the Company was Sued for Fraud - Contact the Firm by July 14 if You Lost MoneyNEW YORK CITY, NY / ACCESS Newswire / June 25, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (
NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance BiotherapeuticsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVANEW YORK CITY, NY / ACCESS Newswire / June 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (
NASDAQ:IOVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Iovance Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - IOVASearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Iovance Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - IOVANEW YORK - June 24, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (
NASDAQ: IOVA) of a class action securities lawsuit.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Krispy Kreme, Strategy Incorporated, Organon, and Iovance and Encourages Investors to Contact the FirmNEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Krispy Kreme, Inc. (
NASDAQ:DNUT), Strategy Incorporated (
NASDAQ:MSTR), Organon & Co. (
NYSE:OGN), and Iovance Biotherapeutics, Inc. (
NASDAQ:IOVA). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)SAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (
NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 20, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 312,660 shares of Iovance’s common stock to 58 new, non-executive employees.
Deadline Approaching for Investors of Iovance Biotherapeutics, Inc. (IOVA) - Contact Kaplan Fox Before July 14, 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Deadline Approaching for Investors of Iovance Biotherapeutics, Inc. (IOVA) - Contact Kaplan Fox Before July 14, 2025NEW YORK, NY - June 23, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (
NASDAQ: IOVA) on behalf of investors that purchased or otherwise acquired Iovance securities between May 9, 2024 and May 8, 2025 (the “Class Period”).
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVANEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (
NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
IOVA FRAUD NOTIFICATION: Did Iovance Biotherapeutics, Inc. Commit Securities Fraud? Investors Are Urged to Contact BFA Law by July 14 to Potentially Recover LossesNEW YORK CITY, NY / ACCESS Newswire / June 23, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (
NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws.
IOVA COURT NEWS: Iovance Biotherapeutics, Inc. Was Sued for Securities Fraud - Investors Are Urged to Contact BFA Law By July 14 Legal DeadlineNEW YORK CITY, NY / ACCESS Newswire / June 20, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (
NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVANEW YORK CITY, NY / ACCESS Newswire / June 20, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (
NASDAQ:IOVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
IOVA COURT NOTICE: Lose Money on Iovance Biotherapeutics, Inc.? Contact BFA Law before Upcoming Class Action DeadlineNEW YORK CITY, NY / ACCESS Newswire / June 19, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (
NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws.
